BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37596912)

  • 1. Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence.
    Zohar Y; Mabjeesh NJ
    Expert Opin Ther Targets; 2023; 27(8):715-731. PubMed ID: 37596912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
    Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
    Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhapontigenin inhibited hypoxia inducible factor 1 alpha accumulation and angiogenesis in hypoxic PC-3 prostate cancer cells.
    Jung DB; Lee HJ; Jeong SJ; Lee HJ; Lee EO; Kim YC; Ahn KS; Chen CY; Kim SH
    Biol Pharm Bull; 2011; 34(6):850-5. PubMed ID: 21628883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
    Reece KM; Richardson ED; Cook KM; Campbell TJ; Pisle ST; Holly AJ; Venzon DJ; Liewehr DJ; Chau CH; Price DK; Figg WD
    Mol Cancer; 2014 Apr; 13():91. PubMed ID: 24775564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1α/Notch1 signaling pathway.
    Wu K; Wu M; Yang H; Diao R; Zeng H
    Clin Transl Oncol; 2023 Jul; 25(7):2138-2152. PubMed ID: 36757381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells.
    Mabjeesh NJ; Shefler A; Amir S; Matzkin H
    Prostate; 2008 May; 68(6):679-89. PubMed ID: 18288682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Sonawane V; Rathos MJ; Kumar S; Joshi KS
    BMC Cancer; 2011 Aug; 11():338. PubMed ID: 21819554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducible factor-1 in human breast and prostate cancer.
    Kimbro KS; Simons JW
    Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics.
    Deep G; Kumar R; Nambiar DK; Jain AK; Ramteke AM; Serkova NJ; Agarwal C; Agarwal R
    Mol Carcinog; 2017 Mar; 56(3):833-848. PubMed ID: 27533043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha.
    Jiang YG; Luo Y; He DL; Li X; Zhang LL; Peng T; Li MC; Lin YH
    Int J Urol; 2007 Nov; 14(11):1034-9. PubMed ID: 17956532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.
    Befani CD; Vlachostergios PJ; Hatzidaki E; Patrikidou A; Bonanou S; Simos G; Papandreou CN; Liakos P
    J Mol Med (Berl); 2012 Jan; 90(1):45-54. PubMed ID: 21909688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides.
    Lin J; Denmeade S; Carducci MA
    Curr Cancer Drug Targets; 2009 Nov; 9(7):881-7. PubMed ID: 20025575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
    Jeong CW; Yoon CY; Jeong SJ; Hong SK; Byun SS; Kwak C; Lee SE
    Urol Oncol; 2013 Nov; 31(8):1448-56. PubMed ID: 22537539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
    Tan C; de Noronha RG; Roecker AJ; Pyrzynska B; Khwaja F; Zhang Z; Zhang H; Teng Q; Nicholson AC; Giannakakou P; Zhou W; Olson JJ; Pereira MM; Nicolaou KC; Van Meir EG
    Cancer Res; 2005 Jan; 65(2):605-12. PubMed ID: 15695405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination.
    Huang H; Benzonana LL; Zhao H; Watts HR; Perry NJ; Bevan C; Brown R; Ma D
    Br J Cancer; 2014 Sep; 111(7):1338-49. PubMed ID: 25072260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer.
    Zhong H; Agani F; Baccala AA; Laughner E; Rioseco-Camacho N; Isaacs WB; Simons JW; Semenza GL
    Cancer Res; 1998 Dec; 58(23):5280-4. PubMed ID: 9850048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
    Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
    Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha).
    Anastasiadis AG; Ghafar MA; Salomon L; Vacherot F; Benedit P; Chen MW; Shabsigh A; Burchardt M; Chopin DK; Shabsigh R; Buttyan R
    J Cancer Res Clin Oncol; 2002 Jul; 128(7):358-62. PubMed ID: 12136249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.